These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 1233520)

  • 21. THE USE OF HALLUCINOGENIC, PSYCHOTOMIMETIC, PSYCHEDELIC DRUGS IN NORTH CAROLINA.
    KEELER MH
    N C Med J; 1963 Dec; 24():555-7. PubMed ID: 14089896
    [No Abstract]   [Full Text] [Related]  

  • 22. Unsurmountable antagonism of brain 5-hydroxytryptamine2 receptors by (+)-lysergic acid diethylamide and bromo-lysergic acid diethylamide.
    Burris KD; Sanders-Bush E
    Mol Pharmacol; 1992 Nov; 42(5):826-30. PubMed ID: 1359397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus.
    Almaula N; Ebersole BJ; Ballesteros JA; Weinstein H; Sealfon SC
    Mol Pharmacol; 1996 Jul; 50(1):34-42. PubMed ID: 8700116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of the hallucinogenic drugs LSD-25 and mescaline on the electroretinogram.
    APTER JT; PFEIFFER CC
    Ann N Y Acad Sci; 1957 Mar; 66(3):508-13; discussion, 513-4. PubMed ID: 13425239
    [No Abstract]   [Full Text] [Related]  

  • 25. Antagonism of d-lysergic acid diethylamide and mescaline by 1-methyl-1, 2, 5, 6-tetrahydropyridine-N, N-diethyl-carboxamide (THPC).
    Dyer DC; Benington F; Morin RD
    Arch Int Pharmacodyn Ther; 1975 Oct; 217(2):197-200. PubMed ID: 127560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new view of the structural relationship between LSD and mescaline.
    Nichols DE; Pfister WR; Yim GK; Cosgrove RJ
    Brain Res Bull; 1977; 2(3):169-71. PubMed ID: 890502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
    De Gregorio D; Aguilar-Valles A; Preller KH; Heifets BD; Hibicke M; Mitchell J; Gobbi G
    J Neurosci; 2021 Feb; 41(5):891-900. PubMed ID: 33257322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2,5-dimethoxy-4-methyl-amphetamine (STP): a new hallucinogenic drug.
    Snyder SH; Faillace L; Hollister L
    Science; 1967 Nov; 158(3801):669-70. PubMed ID: 4860952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor.
    McLean TH; Chambers JJ; Parrish JC; Braden MR; Marona-Lewicka D; Kurrasch-Orbaugh D; Nichols DE
    J Med Chem; 2006 Jul; 49(14):4269-74. PubMed ID: 16821786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychotomimetic drugs: biochemistry and pharmacology.
    Brimblecombe RW
    Adv Drug Res; 1973; 7():165-206. PubMed ID: 4613150
    [No Abstract]   [Full Text] [Related]  

  • 31. [FUNDAMENTALS OF A CONDITIONAL-GENETIC PSYCHOPATHOLOGY AS EXEMPLIFIED BY EXPERIMENTAL PSYCHOSIS].
    LEUNER H
    Nervenarzt; 1963 May; 34():198-206. PubMed ID: 14157764
    [No Abstract]   [Full Text] [Related]  

  • 32. Discriminative stimulus properties of lysergic acid diethylamide in the monkey.
    Nielsen EB
    J Pharmacol Exp Ther; 1985 Jul; 234(1):244-9. PubMed ID: 4009503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The possible role of tryptamine in brain function and its relationship to the actions of LSD-like hallucinogens.
    Martin WR; Sloan JW
    Mt Sinai J Med; 1974; 41(2):276-82. PubMed ID: 4544624
    [No Abstract]   [Full Text] [Related]  

  • 34. HALLUCINOGENS. TOOLS FOR RESEARCH OR THERAPEUTIC AGENTS.
    CHARALAMPOUS KD; KINROSS-WRIGHT J
    Tex State J Med; 1963 Sep; 59():848-52. PubMed ID: 14054727
    [No Abstract]   [Full Text] [Related]  

  • 35. [SEROTONIN AND PSYCHIATRY].
    PELICIER Y
    Pathol Biol; 1964 Nov; 12():1107-9. PubMed ID: 14224288
    [No Abstract]   [Full Text] [Related]  

  • 36. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
    Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
    Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
    [No Abstract]   [Full Text] [Related]  

  • 37. Response of cluster headache to psilocybin and LSD.
    Sewell RA; Halpern JH; Pope HG
    Neurology; 2006 Jun; 66(12):1920-2. PubMed ID: 16801660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CLINICAL SYNDROMES AND BIOCHEMICAL ALTERATIONS FOLLOWING MESCALINE, LYSERGIC ACID DIETHYLAMIDE, PSILOCYBIN AND A COMBINATION OF THE THREE PSYCHOTOMIMETIC DRUGS.
    HOLLISTER LE; SJOBERG BM
    Compr Psychiatry; 1964 Jun; 5():170-8. PubMed ID: 14156873
    [No Abstract]   [Full Text] [Related]  

  • 39. Mescaline: The forgotten psychedelic.
    Vamvakopoulou IA; Narine KAD; Campbell I; Dyck JRB; Nutt DJ
    Neuropharmacology; 2023 Jan; 222():109294. PubMed ID: 36252614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The psychology of hallucinogenic drug discontinuers.
    Salzman C; Lieff J; Kochansky GE; Shader RI
    Am J Psychiatry; 1972 Dec; 129(6):755-61. PubMed ID: 4404760
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.